查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1703464

安德森-塔维尔症候群市场－全球产业规模、份额、趋势、机会和预测，按疾病类型、配销通路、地区和竞争细分，2020-2030 年

Andersen-Tawil Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球安德森-塔维尔症候群 (ATS) 市场价值为 226 万美元，预计到 2030 年将达到 349 万美元，预测期内的年复合成长率(CAGR) 为 7.47%。

市场概览
预测期 2026-2030
2024年市场规模 226万美元
2030年市场规模 349万美元
2025-2030 年复合年增长率 7.47%
成长最快的领域 网路药局
最大的市场 北美洲

人们对罕见遗传疾病的认识不断提高，加上诊断技术的进步，推动了人们对 ATS 市场的兴趣。安德森-塔维尔症候群是一种罕见的遗传性离子通道疾病，会影响骨骼肌、心臟功能和身体发育，常导致週期性麻痹和危及生命的心律不整。医疗保健专业人员的认识不断提高以及基因检测方法的改进使得早期诊断成为可能，这对于及时有效的疾病管理至关重要。

精准医疗和个人化治疗策略的出现正在进一步影响ATS标靶治疗的发展。儘管目前的治疗选择仍然有限，但对钾通道调节剂和基因疗法的持续研究具有巨大的前景。製药公司和研究机构加大对 ATS 患者未满足需求的投资也促进了市场的成长。

关键市场驱动因素

基因诊断的进展

主要市场挑战

症状复杂导致诊断延迟

对于涉及心臟併发症的病例，这些延误尤其有害，因为及时干预对于防止严重后果至关重要。

主要市场趋势

尖端基因诊断和个人化护理

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第 4 章：全球安德森-塔维尔症候群市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依疾病类型（1 型、2 型）
    • 按配销通路（医院药房、零售药房、网路药房）
    • 按地区
    • 按公司分类（2024）
  • 市场地图
    • 依疾病类型
    • 按配销通路
    • 按地区

第五章：亚太地区安德森-塔维尔症候群市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依疾病类型
    • 按配销通路
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第六章：欧洲安德森-塔维尔症候群市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第七章：北美安德森-塔维尔症候群市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第八章：南美安德森-塔维尔症候群市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第九章：中东和非洲安德森-塔维尔症候群市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第十章：市场动态

  • 驱动程式
  • 挑战

第 11 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 12 章：全球安德森-塔维尔症候群市场：SWOT 分析

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章：竞争格局

  • Merck KGA.
  • Grevis Pharmaceuticals
  • Xeris Pharma
  • Novartis AG
  • Advanz Pharmaceuticals
  • Alembic Pharmaceuticals
  • Avet Pharmaceuticals
  • Hikma Pharmaceuticals
  • Micro Labs
  • Advagen Pharma

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 16864

Global Andersen-Tawil Syndrome (ATS) market was valued at USD 2.26 million in 2024 and is projected to reach USD 3.49 million by 2030, growing at a compound annual growth rate (CAGR) of 7.47% during the forecast period.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.26 Million
Market Size 2030USD 3.49 Million
CAGR 2025-20307.47%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Rising awareness of rare genetic disorders, coupled with advancements in diagnostic technologies, is propelling interest in the ATS market. Andersen-Tawil Syndrome is a rare genetic channelopathy that impacts skeletal muscles, cardiac function, and physical development, often resulting in periodic paralysis and life-threatening arrhythmias. Increased recognition among healthcare professionals and improvements in genetic testing methodologies are enabling earlier diagnosis, which is critical for timely and effective disease management.

The emergence of precision medicine and personalized therapeutic strategies is further influencing the development of targeted treatments for ATS. Although current treatment options remain limited, ongoing research into potassium channel modulators and gene therapies holds significant promise. Increased investment from pharmaceutical companies and research institutions focused on addressing the unmet needs of ATS patients is also contributing to market growth.

Key Market Drivers

Advancements in Genetic Diagnostics

The growth of the ATS market is strongly supported by progress in genetic diagnostics and electrophysiology, which have significantly enhanced the identification and understanding of this rare autosomal dominant condition. ATS is primarily caused by mutations affecting potassium ion channels, leading to characteristic symptoms including cardiac arrhythmias, muscle weakness, and distinct physical traits. With an estimated prevalence of 0.08 to 0.1 per 100,000 individuals, accurate diagnosis is essential.

Improvements in next-generation sequencing (NGS) and genetic screening techniques have enabled earlier and more precise detection, resulting in better disease management. Reports indicate that approximately 76% of physicians are utilizing genetic testing for rare diseases, reflecting a growing emphasis on early identification.

The integration of artificial intelligence (AI) into diagnostic workflows is accelerating the identification of rare mutations associated with ATS, facilitating tailored treatment strategies. Furthermore, the development of rare disease registries and patient databases is enriching the collective understanding of disease progression and treatment efficacy. Regulatory support for orphan drug development and accelerated approval pathways is also fostering innovation in therapy development for ATS.

Key Market Challenges

Diagnostic Delays Due to Complex Symptomatology

A primary challenge in the ATS market lies in diagnostic delays, driven by the condition's varied and often ambiguous symptom presentation. Patients may exhibit a broad range of clinical manifestations, including cardiac arrhythmias, episodes of muscle paralysis, and unique facial features-symptoms that, while indicative of ATS, are not exclusive to it.

This clinical variability frequently leads to misdiagnoses, as symptoms may be mistaken for more common cardiac or neuromuscular conditions. Consequently, patients often receive inappropriate treatments that fail to address the underlying genetic cause.

Furthermore, limited awareness of ATS among both the general public and healthcare professionals exacerbates diagnostic delays. Due to the rarity of the condition, physicians may not consider ATS early in the diagnostic process, resulting in prolonged patient journeys involving multiple specialists and extensive testing before a definitive diagnosis is reached.

These delays can be particularly detrimental in cases involving cardiac complications, where timely intervention is essential to prevent severe outcomes.

Key Market Trends

Cutting-Edge Genetic Diagnostics and Personalized Care

Technological advancements in genetic diagnostics-particularly next-generation sequencing (NGS) and whole exome sequencing (WES)-are revolutionizing the diagnosis and management of ATS. These techniques enable the rapid and accurate identification of pathogenic mutations, including those in the KCNJ2 and CACNA1S genes, which are commonly associated with ATS.

As a result, clinicians can now deliver faster, more accurate diagnoses, facilitating timely intervention and access to appropriate treatments. These developments have also deepened scientific understanding of ATS at the molecular level, allowing researchers to explore genotype-phenotype relationships and identify novel therapeutic targets.

This expanding knowledge base is supporting the development of more effective, genetically informed treatments and is accelerating progress toward personalized medicine approaches in the ATS space. Moreover, genetic diagnostics are increasingly being used for carrier screening among family members, enabling early detection, proactive monitoring, and preventative care-further driving demand for ATS-related medical services and diagnostics.

Key Market Players

  • Merck KGA.
  • Grevis Pharmaceuticals
  • Xeris Pharma
  • Novartis AG
  • Advanz Pharmaceuticals
  • Alembic Pharmaceuticals
  • Avet Pharmaceuticals
  • Hikma Pharmaceuticals
  • Micro Labs
  • Advagen Pharma

Report Scope:

In this report, the Global Andersen-Tawil Syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Andersen-Tawil Syndrome Market, By Disease Type:

  • Type 1
  • Type 2

Andersen-Tawil Syndrome Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Andersen-Tawil Syndrome Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Andersen-Tawil Syndrome Market.

Available Customizations:

Global Andersen-Tawil Syndrome Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Andersen-Tawil Syndrome Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Disease Type (Type 1, Type 2)
    • 4.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 4.2.3. By Region
    • 4.2.4. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Disease Type
    • 4.3.2. By Distribution Channel
    • 4.3.3. By Region

5. Asia Pacific Andersen-Tawil Syndrome Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type
    • 5.2.2. By Distribution Channel
    • 5.2.3. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Andersen-Tawil Syndrome Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Disease Type
        • 5.3.1.2.2. By Distribution Channel
    • 5.3.2. India Andersen-Tawil Syndrome Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Disease Type
        • 5.3.2.2.2. By Distribution Channel
    • 5.3.3. Australia Andersen-Tawil Syndrome Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Disease Type
        • 5.3.3.2.2. By Distribution Channel
    • 5.3.4. Japan Andersen-Tawil Syndrome Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Disease Type
        • 5.3.4.2.2. By Distribution Channel
    • 5.3.5. South Korea Andersen-Tawil Syndrome Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Disease Type
        • 5.3.5.2.2. By Distribution Channel

6. Europe Andersen-Tawil Syndrome Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Andersen-Tawil Syndrome Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Germany Andersen-Tawil Syndrome Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Spain Andersen-Tawil Syndrome Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Distribution Channel
    • 6.3.4. Italy Andersen-Tawil Syndrome Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Disease Type
        • 6.3.4.2.2. By Distribution Channel
    • 6.3.5. United Kingdom Andersen-Tawil Syndrome Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Disease Type
        • 6.3.5.2.2. By Distribution Channel

7. North America Andersen-Tawil Syndrome Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Andersen-Tawil Syndrome Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. Mexico Andersen-Tawil Syndrome Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. Canada Andersen-Tawil Syndrome Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Distribution Channel

8. South America Andersen-Tawil Syndrome Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Andersen-Tawil Syndrome Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. Argentina Andersen-Tawil Syndrome Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Colombia Andersen-Tawil Syndrome Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Distribution Channel

9. Middle East and Africa Andersen-Tawil Syndrome Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Andersen-Tawil Syndrome Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Saudi Arabia Andersen-Tawil Syndrome Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. UAE Andersen-Tawil Syndrome Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Distribution Channel

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Andersen-Tawil Syndrome Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Merck KGA.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Grevis Pharmaceuticals
  • 14.3. Xeris Pharma
  • 14.4. Novartis AG
  • 14.5. Advanz Pharmaceuticals
  • 14.6. Alembic Pharmaceuticals
  • 14.7. Avet Pharmaceuticals
  • 14.8. Hikma Pharmaceuticals
  • 14.9. Micro Labs
  • 14.10. Advagen Pharma

15. Strategic Recommendations

16. About Us & Disclaimer